<DOC>
	<DOC>NCT03021265</DOC>
	<brief_summary>Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio® Combination Tablets treatment in patients with hypertension</brief_summary>
	<brief_title>To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension</brief_title>
	<detailed_description>Non-interventional study based on newly collected data. The study will consist of a baseline visit and follow-up visits at Week 4, 8, 12, 24, 36 and 52 for patients who have newly initiated Micatrio® Combination Tablets. The patients will be followed up until discontinuation of Micatrio® Combination Tablets treatment or the end of study. All patients administrated Micatrio® Combination Tablets after the launch at the sites contracted with the sponsor will be registered.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Inclusion criteria: Patients who are prescribed with Micatrio® Combination Tablets by the discretion of investigators based on the Japanese package insert Patients who have never been treated with Micatrio® Combination Tablets before enrolment Exclusion criteria: Patients who are participating/planned to participate in a clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>